bluebird bio Inc (NASDAQ:BLUE) insider Philip D. Gregory sold 850 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $101.20, for a total transaction of $86,020.00. Following the sale, the insider now directly owns 30,692 shares of the company’s stock, valued at approximately $3,106,030.40. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ BLUE traded up $0.22 during mid-day trading on Monday, reaching $99.65. 368,049 shares of the company’s stock were exchanged, compared to its average volume of 543,996. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of -9.33 and a beta of 2.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 8.02 and a current ratio of 8.02. bluebird bio Inc has a 52-week low of $87.49 and a 52-week high of $163.43. The company’s 50-day moving average is $117.68 and its 200-day moving average is $132.45.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($3.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.04) by ($0.51). The company had revenue of $13.30 million during the quarter, compared to analysts’ expectations of $13.13 million. bluebird bio had a negative net margin of 1,158.04% and a negative return on equity of 35.90%. The firm’s quarterly revenue was up 68.4% on a year-over-year basis. During the same quarter last year, the firm posted ($2.91) earnings per share. As a group, equities analysts predict that bluebird bio Inc will post -13.22 earnings per share for the current fiscal year.
A number of research analysts have weighed in on BLUE shares. Morgan Stanley decreased their target price on shares of bluebird bio from $143.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Gabelli reaffirmed a “buy” rating on shares of bluebird bio in a report on Friday, July 19th. BidaskClub downgraded bluebird bio from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. reissued a “buy” rating and set a $195.00 price objective on shares of bluebird bio in a research note on Thursday, June 13th. Finally, Piper Jaffray Companies set a $120.00 target price on bluebird bio and gave the company a “hold” rating in a report on Friday, June 14th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and an average price target of $154.13.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.